CD274 and non-small cell lung carcinoma: Recent advances in immunotherapy, including immune checkpoint blockade (ICB) with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibition, have revolutionized the treatment of non-small cell lung cancer (NSCLC), resulting in durable responses and improved overall survival in a subset of patients.1